Diabetes mellitus type 1 medical therapy
|
Diabetes mellitus type 1 Microchapters |
|
Differentiating Diabetes mellitus type 1 from other Diseases |
|
Diagnosis |
|
Treatment |
|
Cardiovascular Disease and Risk Management |
|
Case Studies |
|
Diabetes mellitus Main page |
|
Patient Information |
|---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3]; Vishal Devarkonda, M.B.B.S[4]; Hibatullah Abdul Aleem, M.B.B.S[5]
Overview
Type 1 diabetes mellitus (T1DM) is characterized by autoimmune destruction of pancreatic beta cells resulting in absolute insulin deficiency, making lifelong exogenous insulin replacement the cornerstone of therapy. Modern management integrates insulin delivery (via multiple daily injections [MDI] or continuous subcutaneous insulin infusion [CSII]), continuous glucose monitoring (CGM), and increasingly, automated insulin delivery (AID) systems. The goals of medical therapy are to eliminate symptoms of hyperglycemia, achieve individualized glycemic targets, minimize hypoglycemia, and reduce long-term microvascular and macrovascular complications. This microchapter covers insulin therapy, glycemic targets, glucose monitoring, prevention of acute glycemic emergencies, adjunctive pharmacotherapy, cardiovascular risk management, diabetes self-management education and support (DSMES), and management in special populations.
Medical Therapy
Treatment Approach
The following algorithm summarizes the current guideline-directed approach to insulin delivery and monitoring in T1DM, reflecting AID systems and CGM as standard of care.[1][2][3]
| Confirmed T1DM — initiate exogenous insulin without delay (life-sustaining; never omit) | |||||||||||||||||||||||
| Start basal-bolus therapy: long-acting basal analog + rapid-acting prandial analog Initial TDD 0.2–0.6 units/kg/day (up to 1.0 if DKA at presentation) | |||||||||||||||||||||||
| Offer CGM at diagnosis to all patients (standard of care) | |||||||||||||||||||||||
| Select insulin delivery method via shared decision-making | |||||||||||||||||||||||
| AID (hybrid closed-loop) - preferred when available and usable safely | CSII (pump) without automation | MDI + CGM, with connected/smart pen if available | |||||||||||||||||||||
| Titrate to individualized targets: TIR >70%, TBR <70 mg/dL <4%, CV ≤36%, HbA1c individualized (~<7% for most) | |||||||||||||||||||||||
| Reassess regularly; reinforce DSMES, carbohydrate counting, sick-day rules, and hypoglycemia/DKA prevention | |||||||||||||||||||||||
| Consider adjunctive pramlintide (only FDA-approved add-on) if postprandial targets unmet; individualize CV risk management | |||||||||||||||||||||||
Abbreviations: AID = automated insulin delivery; CGM = continuous glucose monitoring; CSII = continuous subcutaneous insulin infusion; CV = coefficient of variation; DKA = diabetic ketoacidosis; DSMES = diabetes self-management education and support; HbA1c = glycosylated hemoglobin; MDI = multiple daily injections; TBR = time below range; TDD = total daily dose; TIR = time in range; T1DM = type 1 diabetes mellitus.
Glycemic Targets
Glycemic goals should be individualized through shared decision-making, considering duration of diabetes, comorbidities, hypoglycemia risk, life expectancy, and psychosocial factors.[4][3]
CGM Metrics (International Consensus / ADA)
- Time in range (TIR, 70–180 mg/dL): >70% (roughly corresponds to HbA1c ~7%)[4][3]
- Time in tight range (TITR, 70–140 mg/dL [3.9-7.8 mmol/L]) is an emerging glycemic metric; while no universal goal has been established, a TITR >50% is considered a reasonable target with AID systems.[5][6]
- Time below range (TBR): <70 mg/dL: <4% (<1% for older adults); <54 mg/dL: <1%[4][7]
- Time above range (TAR): >180 mg/dL: <25%; >250 mg/dL: <5%[4][7]
- Coefficient of variation (CV): ≤36% (higher CV associated with increased hypoglycemia risk)[8][3]
- Preprandial glucose: 80-130 mg/dL; 1-2 hour postprandial glucose: <180 mg/dL[4]
Older adults and pediatric patients require modified targets; very complex or poor-health older adults should avoid reliance on HbA1c and focus on avoiding hypoglycemia and symptomatic hyperglycemia.[9][10]
Insulin Therapy
Insulin is essential and life-sustaining in T1DM. The DCCT demonstrated that intensive insulin therapy (HbA1c ~7.3% vs. ~9.1%) reduced microvascular complications by ~50%, with persistent macrovascular benefits over 20+ years of follow-up; however, intensive therapy was associated with a 2–3-fold increase in severe hypoglycemia.[3] Modern insulin analogs are preferred over human insulins (regular, NPH) due to lower hypoglycemia risk, less weight gain, and modestly lower HbA1c (ADA, Level A).[1]
| Category | Examples | Onset | Peak | Duration |
|---|---|---|---|---|
| Rapid-acting analogs (RAA) | Lispro, aspart, glulisine | 15–30 min | 0.5–2.5 hr | 3–5 hr |
| Ultra-rapid-acting analogs (URAA) | Faster aspart (Fiasp), lispro-aabc (Lyumjev) | 15–20 min | 1.5–2.2 hr | 5–7 hr |
| Inhaled insulin | Technosphere insulin (Afrezza) | ~12 min | 0.5–0.9 hr | 1.5–3 hr |
| Short-acting (regular) | Humulin R, Novolin R | 30–60 min | 2–4 hr | 5–8 hr |
| Intermediate-acting | NPH | 1–2 hr | 2–8 hr | 14–24 hr |
| Long-acting analogs | Glargine U-100 (Lantus, Basaglar), detemir (Levemir) | 1–2 hr | No peak | ~24 hr |
| Ultra-long-acting analogs | Glargine U-300 (Toujeo), degludec (Tresiba) | 1–2 hr | No peak | >24–42 hr |
Key points regarding newer formulations:
- Ultra-rapid-acting analogs reduce 1-hour postprandial glucose compared with RAA (estimated treatment difference -16.4 mg/dL for faster aspart vs. aspart) but have not demonstrated additional HbA1c reduction.[8][3]
- Inhaled insulin achieves faster onset and clearance than injectable RAA; contraindicated in chronic obstructive pulmonary disease, asthma, and active smoking. Spirometry is required at baseline, at 6 months, and annually thereafter.[1]
- Ultra-long-acting basal analogs (U-300 glargine, degludec) may confer lower hypoglycemia risk compared with U-100 glargine.[1][11]
Basal-Bolus MDI Regimen
The standard regimen consists of a long-acting basal analog (typically ~30-50% of total daily dose [TDD]) combined with rapid-acting prandial insulin at meals.[1][8]
- Initial TDD: In newly diagnosed adults, insulin requirements at initiation typically range from 0.2 to 0.6 units/kg/day, with lower doses often sufficient during the partial remission (honeymoon) period or when presenting outside of DKA; 0.5 units/kg/day is a typical starting dose in metabolically stable adults. For those presenting with DKA, initial dosing of up to 1.0 unit/kg/day may be required. Higher doses may also be needed during puberty, illness, or the late luteal phase.[1][8]
Prandial Insulin Dosing
Prandial doses are calculated using:[8][7]
- Carbohydrate ratio (ICR): grams of carbohydrate covered by 1 unit of rapid-acting insulin; commonly estimated as 500 ÷ TDD (for rapid-acting insulin) or 450 ÷ TDD (for regular insulin); alternatively, 450 ÷ weight (kg) has been proposed. These are starting estimates only and require empirical adjustment.
- Insulin sensitivity factor (ISF/correction factor): glucose lowering per 1 unit of rapid-acting insulin; commonly estimated as 1800 ÷ TDD (for rapid-acting insulin) or 1500 ÷ TDD (for regular insulin). These are starting estimates only and require empirical adjustment.
- Consider insulin-on-board (active insulin from prior boluses) before giving correction doses to avoid insulin stacking and resultant hypoglycemia; this calculation is automated in smart pens and AID systems.
- Adjustments for anticipated physical activity, illness, and glycemic trends (when using CGM).
Education on carbohydrate counting, food label interpretation, and dose adjustment for protein/fat content is recommended (ADA, Level B).[1]
Insulin Delivery Systems
Continuous Subcutaneous Insulin Infusion (CSII / Insulin Pumps): CSII delivers rapid-acting insulin as a continuous basal rate with user-initiated meal boluses. A systematic review and meta-analysis demonstrated modest HbA1c reduction and reduced severe hypoglycemia compared with MDI, along with improved quality of life.[1]
Automated Insulin Delivery (AID) Systems: AID systems integrate an insulin pump, CGM, and a control algorithm that automatically adjusts basal insulin delivery based on real-time glucose levels. These hybrid closed-loop (HCL) systems represent the current standard of care for insulin delivery in T1DM (ADA, Level A).[1][2]
- RCTs and real-world studies consistently demonstrate that AID systems increase TIR by ~10–15 percentage points, reduce HbA1c by 0.3-0.7%, and decrease time in hypoglycemia compared with standard pump or MDI therapy.[2][5][12]
- A meta-analysis found HCL systems increased TIR by 8.8% and reduced time above 180 mg/dL by 7.8% compared with sensor-augmented pump therapy.[12]
- Benefits are greatest in those with the highest baseline HbA1c or lowest baseline TIR; AID systems also improve psychosocial outcomes, reduce diabetes distress and fear of hypoglycemia, and are cost-effective.[2]
- AID systems should be offered to all individuals with T1DM who can use them safely, independently or with caregiver support (ADA, Level A).[1]
Currently available FDA-cleared AID systems include MiniMed 780G, Tandem Control-IQ, Omnipod 5, and CamAPS FX, with distinct performance profiles across glycemic metrics.[13]
Connected Insulin Pens: Smart pens with dose tracking and CGM integration are an alternative for individuals on MDI who prefer not to use a pump, providing dose logging and insulin-on-board calculations.
Continuous Glucose Monitoring
CGM is now considered standard of care for all individuals with T1DM (ADA, Level A) and should be offered at diagnosis or as soon as possible.[1][4][10] Integration of CGM into the treatment plan improves glycemic outcomes, decreases hypoglycemic events, and improves quality of life. A 10-14 day CGM assessment with ≥70% wear time provides reliable glycemic data for clinical management.[4]
Prevention of Acute Glycemic Emergencies
Diabetic Ketoacidosis (DKA): DKA prevention centers on never omitting basal insulin, structured sick-day rules (frequent glucose and ketone monitoring, supplemental insulin, hydration, and carbohydrate intake during illness), and patient education on early recognition. Approximately 10% of presentations are euglycemic, particularly with SGLT2 inhibitor use, pregnancy, or reduced carbohydrate intake. For the acute inpatient management protocol (IV fluids, insulin infusion, electrolyte replacement, and transition to subcutaneous insulin), see Diabetic ketoacidosis.[14][15]
Hypoglycemia: The ADA classifies hypoglycemia in three levels:
- Level 1- glucose <70 mg/dL and ≥54 mg/dL; alert value.
- Level 2- glucose <54 mg/dL; clinically significant, requires immediate action.
- Level 3- severe event with altered mental or physical status requiring assistance, irrespective of glucose level.[4]
Glucagon should be prescribed for all individuals on insulin; caregivers and school personnel should be trained in its use.[1]
Adjunctive (Noninsulin) Pharmacotherapy
Pramlintide is the only FDA-approved noninsulin adjunctive therapy for T1DM in the U.S. It is an amylin analog that slows gastric emptying and suppresses postprandial glucagon secretion, providing modest HbA1c reduction (0.3–0.4%) and weight loss (~0.5–2 kg across sources). Use is limited by the need for additional mealtime injections and gastrointestinal side effects.[1][8][5]
Agents not FDA-approved for T1DM (off-label use):
- GLP-1 receptor agonists (e.g., liraglutide): HbA1c reduction ~0.28–0.4%, weight loss ~4–5 kg, insulin dose reduction; limited by gastrointestinal side effects and higher rates of DKA and ketosis.[1][8][16]
- SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) and SGLT1/2 inhibitors (sotagliflozin): HbA1c reduction ~0.4–0.5%, weight loss ~2–3 kg, blood pressure reduction; however, associated with a significantly increased risk of DKA (2–8-fold). Sotagliflozin is approved in Europe for adults with T1DM and BMI ≥27 kg/m² but is contraindicated in T1DM in the U.S. due to DKA risk.[1][16]
- Metformin: does not sustainably improve HbA1c in T1DM; modest weight loss (~1–2 kg) and insulin dose reduction.[1][8]
A 2026 systematic review and meta-analysis of 90 studies concluded that GLP-1 RAs and SGLT2 inhibitors provide consistent but clinically modest metabolic benefits beyond insulin alone, supporting selective rather than broad use in carefully chosen patients within structured monitoring frameworks.[16] Prospective studies evaluating incretin-based therapies (including semaglutide and tirzepatide) for cardiovascular and kidney outcomes in T1DM are ongoing.[1]
Cardiovascular Risk Management
T1DM confers substantially elevated cardiovascular risk, particularly with long disease duration. Management follows a multifactorial approach.[3][17][8]
- Blood pressure: first-line agents are ACE inhibitors or ARBs (especially with albuminuria), combined with lifestyle modification (DASH diet, sodium restriction).
- Lipid management: moderate-intensity statin therapy for adults ≥40 years regardless of estimated ASCVD risk; consider statin therapy in adults 20-39 years with additional ASCVD risk factors or T1DM duration ≥20 years, albuminuria, or reduced eGFR. Children ≥10 years: statin if LDL >160 mg/dL, or >130 mg/dL with cardiovascular risk factors, after 6 months of lifestyle modification.
- Antiplatelet therapy: aspirin for secondary prevention in established CVD; primary prevention benefit should be balanced against bleeding risk.
LDL Cholesterol Goals in Diabetes (2026 ACC/AHA/Multisociety Dyslipidemia Guideline)
| Class I |
| 1. In adults 40-75 years of age with diabetes on moderate-intensity statin therapy, an LDL-C goal of <100 mg/dL is recommended. (Level of Evidence: A) [18] |
| Class IIa |
| 1. In adults with diabetes and multiple ASCVD risk factors on high-intensity statin therapy, an LDL-C goal of <70 mg/dL is reasonable. (Level of Evidence: B-R) [18] |
Diabetes Self-Management Education and Support (DSMES)
DSMES is an essential component of T1DM care that enables all other interventions to work optimally (ADA, Level A).[19][3] Key content areas include carbohydrate counting, insulin dose adjustment, CGM/pump use, hypoglycemia recognition and treatment, DKA prevention, sick-day management, and healthy coping. DSMES should be provided at diagnosis, annually, when not meeting treatment goals, during life transitions, and when complications develop. Structured programs (e.g., DAFNE) have demonstrated improved HbA1c without increased severe hypoglycemia, reduced DKA rates, and improved quality of life.[20] Telehealth-based DSMES produces comparable or superior outcomes to in-person delivery (HbA1c reduction −0.30%; 95% CI −0.42 to −0.19 vs. control).[19]
Physical activity is recommended for all individuals with T1DM but requires proactive insulin and carbohydrate adjustments to prevent exercise-related hypoglycemia; strategies include reducing prandial insulin before exercise, consuming supplemental carbohydrates, and using CGM trend data.[3] By expert consensus, exercise can generally be started when glucose is 90–250 mg/dL; above 250 mg/dL exercise may still proceed if ketones are negative, and it should be postponed when glucose exceeds 350 mg/dL with ketones present.[21][10] Screening for diabetes distress, depression, disordered eating, and fear of hypoglycemia should be integrated into routine care.[3][19]
Special Populations
Pregnancy
Preconception counseling and optimization of glycemic control before conception are critical. High-dose folic acid (5 mg/day) should be initiated at least 1 month before conception and continued through the first trimester to reduce the risk of neural tube defects.[3][22][23]
- Glycemic targets: HbA1c <6% if achievable without significant hypoglycemia (may relax to <7%); fasting glucose <95 mg/dL; 1-hour postprandial <140 mg/dL; 2-hour postprandial <120 mg/dL; CGM TIR (63–140 mg/dL) >70% (ADA, Level A).[3][23]
- Insulin requirements typically decrease in early pregnancy (increased hypoglycemia risk), then increase linearly by ~5% per week from ~16 weeks through week 36, often doubling the prepregnancy dose. Both MDI and CSII are acceptable delivery strategies.
- AID systems with pregnancy-specific algorithms show promise, but most current systems lack pregnancy-specific glucose targets.[23][24]
- Insulin formulations with the most pregnancy data include aspart, lispro, glargine, and NPH. Faster aspart showed higher TIR and less severe hypoglycemia compared with aspart in a secondary analysis of pregnant women with T1DM.
Inpatient Management
Individuals with T1DM should never have insulin completely discontinued in the hospital setting due to the risk of DKA; basal insulin must be continued even when NPO. CGM use in the hospital is increasingly supported.[14]
Clinical Pearls
- Never discontinue basal insulin in a patient with T1DM, even when NPO or during illness — this is the most common precipitant of DKA.
- Euglycemic DKA (~10% of DKA presentations) can occur with near-normal glucose, particularly with SGLT2 inhibitor use, pregnancy, or reduced carbohydrate intake.[14]
- The "500 rule" (ICR = 500 ÷ TDD) and "1800 rule" (ISF = 1800 ÷ TDD) are starting estimates only; titrate based on individual response and CGM data.
- CV ≤36% on CGM is a key safety metric; higher variability is associated with increased severe hypoglycemia risk.[8][3]
- Overbasalization — suspect when there is a large bedtime-to-morning glucose differential, frequent nocturnal hypoglycemia, or high glycemic variability; redistribute insulin toward prandial dosing.[1]
- Statin therapy should be considered for all adults with T1DM aged ≥40 years and for younger adults with additional risk factors or long disease duration (≥20 years).[3][17]
Common Pitfalls
- Misdiagnosis as type 2 diabetes in adults: Adult-onset T1DM is frequently misclassified; check islet autoantibodies and C-peptide when clinical features are atypical (normal BMI, rapid progression to insulin requirement, DKA at presentation).
- Failure to prescribe glucagon: All patients on insulin should have glucagon prescribed; caregivers must be trained in its use.
- Inadequate DKA transition: Stopping IV insulin without adequate subcutaneous insulin overlap (30–60 minutes) leads to DKA recurrence.
- Ignoring psychosocial burden: Diabetes distress, burnout, and disordered eating are highly prevalent and directly impair glycemic outcomes; routine screening is essential.
- Delaying technology adoption: CGM and AID systems have robust evidence for benefit across all age groups; cost and access barriers should be actively addressed rather than accepted.
- Using SGLT2 inhibitors without DKA risk mitigation: If used off-label, requires structured education on ketone monitoring, insulin dose maintenance, and sick-day rules.
- Applying type 2 diabetes cardiovascular risk calculators to T1DM: Standard ASCVD risk calculators may underestimate risk in T1DM; T1DM-specific risk tools should be considered when available.
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 American Diabetes Association Professional Practice Committee (2026). "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S183–S215. doi:10.2337/dc26-S009.
- ↑ 2.0 2.1 2.2 2.3 American Diabetes Association Professional Practice Committee (2026). "7. Diabetes Technology: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S150–S165. doi:10.2337/dc26-S007.
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 Holt RIG, DeVries JH, Hess-Fischl A; et al. (2021). "The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetes Care. 44 (11): 2589–2625. doi:10.2337/dci21-0043. PMID 34593612 Check
|pmid=value (help). - ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 American Diabetes Association Professional Practice Committee (2026). "6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S132–S149. doi:10.2337/dc26-S006.
- ↑ 5.0 5.1 5.2 Ziegler AG, Cengiz E, Kay TWH (2025). "The Future of Type 1 Diabetes Therapy". Lancet. 406 (10511): 1520–1534. doi:10.1016/S0140-6736(25)01438-2.
- ↑ Castañeda J, de Galan BE, van Kuijk SMJ; et al. (2024). "The Interdependence of Targets for Continuous Glucose Monitoring Outcomes in Type 1 Diabetes With Automated Insulin Delivery". Diabetes Obes Metab. 26 (12): 5836–5844. doi:10.1111/dom.15955.
- ↑ 7.0 7.1 7.2 Blonde L, Umpierrez GE, Reddy SS; et al. (2022). "American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update". Endocr Pract. 28 (10): 923–1049. doi:10.1016/j.eprac.2022.08.002. PMID 35963508 Check
|pmid=value (help). - ↑ 8.00 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.09 Jacobsen LM, Schatz DA (2026). "Type 1 Diabetes: A Review". JAMA. doi:10.1001/jama.2026.0048.
- ↑ American Diabetes Association Professional Practice Committee (2026). "13. Older Adults: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S277–S296. doi:10.2337/dc26-S013.
- ↑ 10.0 10.1 10.2 American Diabetes Association Professional Practice Committee (2026). "14. Children and Adolescents: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S297–S320. doi:10.2337/dc26-S014. PMID 41358890 Check
|pmid=value (help). - ↑ Vliebergh J, Lefever E, Mathieu C (2021). "Advances in Newer Basal and Bolus Insulins: Impact on Type 1 Diabetes". Curr Opin Endocrinol Diabetes Obes. 28 (1): 1–7. doi:10.1097/MED.0000000000000599. PMID 33315628 Check
|pmid=value (help). - ↑ 12.0 12.1 Sidki AS, Highton PJ, O'Mahoney LL, Wilkinson TJ (2026). "Hybrid Closed-Loop Insulin Delivery Improves Glycaemic Control Compared With Sensor-Augmented Pump Therapy: A Meta-Analysis of 'Free-Living' Randomised Trials in Type 1 Diabetes". Diabet Med. 43 (3): e70210. doi:10.1111/dme.70210. PMID 41527459 Check
|pmid=value (help). - ↑ Di Molfetta S, Di Gioia L, Caruso I; et al. (2024). "Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis". Diabetes Metab Res Rev. 40 (6): e3842. doi:10.1002/dmrr.3842.
- ↑ 14.0 14.1 14.2 American Diabetes Association Professional Practice Committee (2026). "16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S339–S355. doi:10.2337/dc26-S016.
- ↑ Veauthier B, Levy-Grau B (2024). "Diabetic Ketoacidosis: Evaluation and Treatment". Am Fam Physician. 110 (5): 476–486.
- ↑ 16.0 16.1 16.2 Abdel-Rahman SM, Al-Shiab R, Shah E; et al. (2026). "Efficacy and Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Systematic Review and Meta-Analysis". Diabetes Obes Metab. 28 (4): 3165–3181. doi:10.1111/dom.70506.
- ↑ 17.0 17.1 Manrique-Acevedo C, Hirsch IB, Eckel RH (2024). "Prevention of Cardiovascular Disease in Type 1 Diabetes". N Engl J Med. 390 (13): 1207–1217. doi:10.1056/NEJMra2311526. PMID 38598575 Check
|pmid=value (help). - ↑ 18.0 18.1 Blumenthal RS, Morris PB, Gaudino M; et al. (2026). "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol. 87 (19): 2624–2757. doi:10.1016/j.jacc.2025.11.016. PMID 41824590 Check
|pmid=value (help). - ↑ 19.0 19.1 19.2 American Diabetes Association Professional Practice Committee (2026). "5. Facilitating Positive Health Behaviors and Well-Being to Improve Health Outcomes: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S89–S131. doi:10.2337/dc26-S005.
- ↑ Chatterjee S, Davies MJ, Heller S; et al. (2018). "Diabetes Structured Self-Management Education Programmes: A Narrative Review and Current Innovations". Lancet Diabetes Endocrinol. 6 (2): 130–142. doi:10.1016/S2213-8587(17)30239-5. PMID 28970034.
- ↑ Riddell MC, Gallen IW, Smart CE; et al. (2017). "Exercise Management in Type 1 Diabetes: A Consensus Statement". Lancet Diabetes Endocrinol. 5 (5): 377–390. doi:10.1016/S2213-8587(17)30014-1. PMID 28126459.
- ↑ Alexopoulos AS, Blair R, Peters AL (2019). "Management of Preexisting Diabetes in Pregnancy". JAMA. 321 (18): 1811–1819. doi:10.1001/jama.2019.4981. PMID 31087027.
- ↑ 23.0 23.1 23.2 American Diabetes Association Professional Practice Committee (2026). "15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2026". Diabetes Care. 49 (Suppl 1): S321–S338. doi:10.2337/dc26-S015. PMID 41358885 Check
|pmid=value (help). - ↑ Wyckoff JA, Lapolla A, Asias-Dinh BD; et al. (2025). "Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline". J Clin Endocrinol Metab. 110 (9): 2405–2452. doi:10.1210/clinem/dgaf288.